Hay Douglas W P, Giardina Giuseppe A M, Griswold Don E, Underwood David C, Kotzer Charles J, Bush Brian, Potts William, Sandhu Punam, Lundberg Dave, Foley James J, Schmidt Dulcie B, Martin Lenox D, Kilian David, Legos Jeffrey J, Barone Frank C, Luttmann Mark A, Grugni Mario, Raveglia Luca F, Sarau Henry M
GlaxoSmithKline, Department of Pulmonary Biology, King of Prussia, Pennsylvania 19406, USA.
J Pharmacol Exp Ther. 2002 Jan;300(1):314-23. doi: 10.1124/jpet.300.1.314.
In this report the in vitro and in vivo pharmacological and pharmacokinetic profile of (-)-(S)-N-(alpha-ethylbenzyl)-3-(carboxymethoxy)-2-phenylquinoline-4-carboxamide (SB 235375), a low central nervous system (CNS)-penetrant, human neurokinin-3 (NK-3) receptor (hNK-3R) antagonist, is described. SB 235375 inhibited (125)I-[MePhe(7)]-neurokinin B (NKB) binding to membranes of Chinese hamster ovary (CHO) cells expressing the hNK-3R (CHO-hNK-3R) with a K(i) = 2.2 nM and antagonized competitively NKB-induced Ca(2+) mobilization in human embryonic kidney (HEK) 293 cells expressing the hNK-3R (HEK 293-hNK-3R) with a K(b) = 12 nM. SB 235375 antagonized senktide (NK-3R)-induced contractions in rabbit isolated iris sphincter (pA(2) = 8.1) and guinea pig ileal circular smooth muscles (pA(2) = 8.3). SB 235375 was selective for the hNK-3R compared with hNK-1 (K(i) > 100,000 nM) and hNK-2 receptors (K(i) = 209 nM), and was without effect, at 1 microM, in 68 other receptor, enzyme, and ion channel assays. Intravenous SB 235375 produced a dose-related inhibition of miosis induced by i.v. senktide in the rabbit (ED(50) of 0.56 mg/kg). Intraperitoneal SB 235375 (10-30 mg/kg) inhibited citric acid-induced cough and airways hyper-reactivity in guinea pigs. In mice oral SB 235375 (3-30 mg/kg) was without significant effect on the behavioral responses induced by intracerebral ventricular administration of senktide. Pharmacokinetic evaluation in the mouse and rat revealed that oral SB 235375 was well absorbed systemically but did not effectively cross the blood-brain barrier. The preclinical profile of SB 235375, encompassing high affinity, selectivity, oral activity, and low CNS penetration, suggests that it is an appropriate tool compound to define the pathophysiological roles of the NK-3Rs in the peripheral nervous system.
在本报告中,描述了(-)-(S)-N-(α-乙基苄基)-3-(羧基甲氧基)-2-苯基喹啉-4-甲酰胺(SB 235375)的体外和体内药理学及药代动力学特征,它是一种低中枢神经系统(CNS)渗透性的人神经激肽-3(NK-3)受体(hNK-3R)拮抗剂。SB 235375抑制(125)I-[MePhe(7)]-神经激肽B(NKB)与表达hNK-3R的中国仓鼠卵巢(CHO)细胞膜(CHO-hNK-3R)的结合,其解离常数(Ki)=2.2 nM,并在表达hNK-3R的人胚肾(HEK)293细胞(HEK 293-hNK-3R)中竞争性拮抗NKB诱导的Ca(2+)动员,其平衡解离常数(Kb)=12 nM。SB 235375拮抗兔离体虹膜括约肌中senktide(NK-3R)诱导的收缩(pA(2)=8.1)和豚鼠回肠环形平滑肌中senktide诱导的收缩(pA(2)=8.3)。与hNK-1受体(Ki>100,000 nM)和hNK-2受体(Ki=209 nM)相比,SB 235375对hNK-3R具有选择性,并且在1μM浓度下,在其他68种受体、酶和离子通道试验中无作用。静脉注射SB 235375对兔静脉注射senktide诱导的瞳孔缩小产生剂量相关的抑制作用(半数有效剂量(ED(50))为0.56 mg/kg)。腹腔注射SB 235375(10 - 30 mg/kg)可抑制柠檬酸诱导的豚鼠咳嗽和气道高反应性。在小鼠中,口服SB 235375(3 - 30 mg/kg)对脑室内注射senktide诱导的行为反应无显著影响。在小鼠和大鼠中的药代动力学评估显示,口服SB 235375在全身吸收良好,但不能有效穿过血脑屏障。SB 235375的临床前特征包括高亲和力、选择性、口服活性和低CNS渗透性,表明它是确定NK-3R在外周神经系统中病理生理作用的合适工具化合物。